Drugs / camphor
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06444594 | Jul 2024 → Dec 2025 overdue | premature aging syndrome | Penn State University | Recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT00299559 | Mar → Aug 2006 | common cold | Technical University Dresden | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT02581397 | May 2015 → Dec 2016 | — | Ache Laboratorios Farmaceuticos S.A. | Terminated | No outcome recorded |
| Phase 3 | NCT01119534 | May → Oct 2011 | — | Azidus Brasil | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | camphor | “Each Suppository Transpulmin contains eucalyptol, menthol, camphor and guaiacol.” NCT02581397 ↗ |
| Action | Activate | “TRP channel agonists including menthol, capsaicin and camphor” NCT06444594 ↗ |
| Route | Topical | “application to skin” NCT00299559 ↗ |